Aarhus University Seal / Aarhus Universitets segl

The Novo Nordisk Foundation gives DKK 15 million towards research into bowel cancer

Professor, PhD, Claus Lindbjerg Andersen and Professor Søren Laurberg from Aarhus University and Aarhus University Hospital will use the millions of kroner from the Novo Nordisk Foundation to improve the treatment of bowel cancer.

2017.04.05 | Henriette Stevnhøj

Even though the treatment of bowel cancer in Denmark shows good results, two researchers from Aarhus University have ambitions to make it even better. A grant of DKK 15 million from the Novo Nordisk Foundation will now help them on their way.

AU professors Claus Lindbjerg Andersen and Søren Laurberg have developed a blood-based measurement method that can reveal whether there is bowel cancer DNA in the blood of patients who have undergone an operation for bowel cancer. DNA from bowel cancer in the blood means that the patient has residual disease and therefore a very high risk of suffering a relapse. This group of patients would benefit from additional treatment such as chemotherapy.

The aim of the grant is to improve diagnostic imaging and surgery, so that there are fewer patients with residual disease following surgery. The new measurement method will improve the selection of patients who will benefit from chemotherapy following an operation. 

The Novo Nordisk Foundation grant recipient listing


Professor Claus Lindbjerg Andersen
Aarhus University, Department of Clinical Medicine
Aarhus University Hospital, Department of Molecular Medicine
(+45) 7845 5319




Grants and awards, Health and disease, Academic staff, Department of Clinical Medicine, Health, Technical / administrative staff, Health, PhD students, External target group, Public/Media